Long Noncoding RNA LINC00626 Drives Oxaliplatin Resistance in Liver Cancer Cells

A long noncoding RNA called LINC00626 appears to help hepatocellular carcinoma cells tolerate oxaliplatin, a chemotherapy drug used in selected patients with this liver cancer, according to a study published in Discover Oncology. The work links elevated LINC00626 to increased STAT3 Tyr705 phosphorylation and heightened expression of the chemokine CCL20, forming a signaling chain that the researchers associate with an oxaliplatin-tolerant phenotype in HCC cells.

Oxaliplatin-containing regimens are used in selected patients with hepatocellular carcinoma, although acquired resistance can curtail their effectiveness. The research team set out to determine whether LINC00626 contributes to the oxaliplatin response and to investigate the signaling mechanism involved. To do so, they evaluated LINC00626 across public HCC datasets, clinical specimens, parental cell lines, and an oxaliplatin-resistant Hep3B derivative that the team generated for the study.

The results showed that LINC00626 was elevated in HCC specimens and in the resistant Hep3B/OXA cells. Its levels increased after oxaliplatin exposure, and higher expression correlated with unfavorable clinicopathological characteristics in the clinical samples. When the researchers silenced LINC00626, malignant behavior was restrained, oxaliplatin responsiveness increased, and xenograft growth was reduced. Overexpression of the RNA produced reciprocal effects, strengthening malignant features and drug tolerance.

Mechanistically, the study found that LINC00626 primarily enhanced phosphorylation of STAT3 at the Tyr705 residue and promoted the nuclear enrichment of this transcription factor rather than increasing STAT3 transcription itself. Alongside this change, the researchers observed a parallel increase in CCL20 expression and in CCL20 promoter-reporter activity, suggesting that the STAT3 pathway was driving transcription from the CCL20 promoter.

To test whether STAT3 was genuinely required for these effects, the team used several independent approaches. STAT3 depletion weakened the LINC00626-driven phenotype, as did treatment with Stattic, a small-molecule STAT3 inhibitor. A Y705F mutant of STAT3, in which the tyrosine at position 705 is replaced by phenylalanine and cannot be phosphorylated at that site, also weakened the effects. These converging experiments support the conclusion that STAT3 Tyr705 phosphorylation is a key node in the pathway.

Downstream of STAT3, the chemokine CCL20 emerged as a functional mediator. When the researchers knocked down CCL20, they observed a reduction in the abundance of CD133 and CD44, cell surface markers often associated with stem-like properties in cancer cells, and a decline in tumorsphere formation, a laboratory measure of self-renewal capacity. Importantly, CCL20 knockdown counteracted the oxaliplatin-tolerant phenotype that LINC00626 drives, positioning CCL20 as a downstream effector in the resistance mechanism.

The functional work relied on a broad experimental toolkit. Beyond bidirectional genetic manipulation of LINC00626, the study employed transcriptome profiling to map gene expression changes, subcellular fractionation and immunofluorescence to track STAT3 localization, CCL20 promoter-reporter experiments to measure transcriptional activity, and subcutaneous xenografts to assess tumor growth in vivo. This combination of in vitro and in vivo approaches allowed the team to connect molecular observations to tumor-level outcomes.

The authors conclude that these findings associate LINC00626-dependent oxaliplatin tolerance with STAT3 Tyr705 phosphorylation and CCL20 expression in HCC cells. The study is framed as an association rather than a definitive causal demonstration in patients, and the xenograft experiments were performed in subcutaneous models rather than orthotopic liver tumors. Because the work was conducted in cell lines, clinical specimens, and animal models, translating these observations into therapeutic strategies for patients would require further investigation.

Nevertheless, the study adds to a growing body of work implicating long noncoding RNAs in chemotherapy resistance. By identifying a specific RNA-STAT3-CCL20 axis, the research provides a molecular framework that could guide future studies into why some hepatocellular carcinomas become refractory to oxaliplatin-based treatment and how that tolerance might be reversed.

Subject of Research: A study of how the long noncoding RNA LINC00626 promotes oxaliplatin resistance in hepatocellular carcinoma through STAT3 Tyr705 phosphorylation and CCL20 expression.

Article Title: LINC00626 promotes oxaliplatin resistance in hepatocellular carcinoma in association with STAT3 Tyr705 phosphorylation and CCL20 expression

Article References: Li, L., Yu, F., Wang, S., Liu, Z., Qiang, H., Li, X., & Liu, Z. (2026). LINC00626 promotes oxaliplatin resistance in hepatocellular carcinoma in association with STAT3 Tyr705 phosphorylation and CCL20 expression. Discover Oncology. https://doi.org/10.1007/s12672-026-06254-9

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06254-9

Keywords: hepatocellular carcinoma, LINC00626, oxaliplatin resistance, STAT3, CCL20, long noncoding RNA, chemotherapy resistance, tumorsphere, CD133, CD44, xenograft, Discover Oncology